Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities. Get Free Email Updates

Stay Competitive With Stock Market Updates!

Get Free Updates

Largest Pharmaceutical Deal Ever to Take Place Between Bristol-Myers and Celgene

By John F. Heerdink, Jr.
In the biggest pharmaceutical deal ever, Bristol-Myers Squibb will buy Celgene for $74 billion, combining two the largest cancer drug businesses in the world. Wall Street analysts have questioned whether this merge would solve the individual challenges the two companies face. The companies have stated that the combination would create $2.5 billion in cost savings, as well as significantly increase earnings. Due to clinical setbacks and some other misshaps, Bristol-Myers shares fell 15.2 percent in 2018. Celgene saw its shares nosedive nearly 40 percent last year. With Merck & Co’s cancer immunotherapy and growth driver Keytruda dominating the market, Bristol’s Opdivo seems to have lost its luster in the oncology market. Thursday saw Bristol’s stock drop another 13.3 percent lower, ending at $45.12. Many shareholders show concern that current drugs in development for the company may not have high enough sales to offset the major products losing exclusivity between 2022 and 2026. Bristol’s Revlimid, which is expected to make about $10 billion in 2018 in sales, does appear to generate enough cash flow for the company to pay down debt and position for another transaction. Celgene shares rose 20.7 percent. With the deal, Celgene shareholders will each receive one Bristol-Myers Squibb share and $50 cash for each share held or $102.43 per share. The shareholders of Celgene will also receive a contingent value right payment of $9 if three treatments that are currently in development achieve timely approvals. What is most important to the two companies in the merger is maintaining sustainability of Celgene’s leardership role in hematology. Further details into the combination of Bristol-Myers Squibb and Celgene can be found here. This has defintely set the tone in the biotech industry for 2019 and certainly this week during the largest healthcare industry conference in the world,  the  JPMorgan Helathcare Conference in San Francisco. Photo of Multi Colored Basketball Court Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives. Stay Informed! Stay Competitive! Join us at Vista Partners! It’s FREE to receive email updates.

Bristol-Myers to buy Celgene for $74 billion in largest biopharma deal

Both Bristol-Myers and Celgene face separate challenges, and some Wall Street analysts questioned whether the combination – which the companies said would create $2.5 billion in cost savings and significantly raise earnings – would solve them. Amid clinical setbacks and other missteps, Bristol-Myers..
Read Full Article


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us